newsfilter
← Latest News
GlobeNewswire·

Exicure Announces Strategic Expansion into Parkinson’s Disease

  • Exicure, Inc. announced a Strategic Business Expansion & Investment Agreement with NeuroQ Biologics Inc. & Laonz Co., Ltd. on November 19, 2026, to enter the Parkinson's disease medical device market.
  • The partnership centers on X-CUE, an augmented-reality smart-glasses technology developed over a decade to assist patients experiencing freezing of gait.
  • X-CUE has completed its development phase for its third-revised version & is ready for clinical trials with an anticipated evaluation period of approximately six months.
  • Under the agreement, Exicure intends to acquire an equity interest ranging from 20% to 100% in NeuroQ, primarily through issuing common shares in exchange for NeuroQ shares held by Laonz.
  • Final acquisition percentages & transaction terms remain subject to subsequent written agreements, regulatory approvals, & Nasdaq requirements.
  • Exicure plans to provide up to US$500,000 in development funding to support X-CUE's clinical evaluation, regulatory advancement, manufacturing preparation, & commercialization.
  • Laonz has transferred the X-CUE business, including intellectual property & assets, to NeuroQ, which will lead continued development & commercialization with strategic support from Exicure.
  • Exicure is expanding its portfolio beyond its existing stem cell mobilization programs to include medical device technologies addressing unmet needs in Parkinson's disease.
Company
Exicure, Inc.
Keywords
Nasdaq:XCUR, Exicure, Inc., Exicure, XCUR, Parkinson's disease, X-CUE, smart glasses, augmented reality, NeuroQ Biologics, Laonz, clinical trials